|
1
|
Lazaridis K and Tzartos SJ: Autoantibody
specificities in myasthenia gravis; Implications for improved
diagnostics and therapeutics. Front Immunol. 11(212)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gilhus NE, Tzartos S, Evoli A, Palace J,
Burns TM and Verschuuren JJGM: Myasthenia gravis. Nat Rev Dis
Primers. 5(30)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Berrih-Aknin S and Le Panse R: Myasthenia
gravis: A comprehensive review of immune dysregulation and
etiological mechanisms. J Autoimmun. 52:90–100. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Golfinopoulou R, Papageorgiou L,
Efthimiadou A, Bacopoulou F, Chrousos GP, Eliopoulos E and
Vlachakis D: Clinical Genomic, phenotype and epigenetic insights
into the pathology, autoimmunity and weight management of patients
with Myasthenia Gravis (Review). Mol Med Rep.
24(512)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Evoli A and Damato V: Conventional and
emerging treatments and controversies in myasthenia gravis. Expert
Rev Neurother. 23:445–456. 2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hussain Y and Khan H (eds):
Immunosuppressive drugs. Encyclopedia of infection and immunity,
Vol. 4, p726-740, 2022.
|
|
7
|
Lee WS, Lee SI, Lee MS, Kim SI, Lee SS and
Yoo WH: Efficacy and safety of low-dose tacrolimus for active
rheumatoid arthritis with an inadequate response to methotrexate.
Korean J Intern Med. 31:779–787. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sanders DB and Evoli A: Immunosuppressive
therapies in myasthenia gravis. Autoimmunity. 43:428–435.
2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gelfand EW: Intravenous immune globulin in
autoimmune and inflammatory diseases. N Engl J Med. 367:2015–2025.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Gajdos P, Chevret S, Clair B, Tranchant C
and Chastang C: Clinical trial of plasma exchange and high-dose
intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis
Clinical Study Group. Ann Neurol. 41:789–796. 1997.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Skeie GO, Apostolski S, Evoli A, Gilhus
NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J and
Horge HW: European Federation of Neurological Societies. Guidelines
for treatment of autoimmune neuromuscular transmission disorders.
Eur J Neurol. 17:893–902. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sanders DB, Wolfe GI, Benatar M, Evoli A,
Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, et al:
International consensus guidance for management of myasthenia
gravis: Executive summary. Neurology. 87:419–425. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lazaridis K, Dalianoudis I, Baltatzidi V
and Tzartos SJ: Specific removal of autoantibodies by
extracorporeal immunoadsorption ameliorates experimental autoimmune
myasthenia gravis. J Neuroimmunol. 312:24–30. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mantegazza R, Bonanno S, Camera G and
Antozzi C: Current and emerging therapies for the treatment of
myasthenia gravis. Neuropsychiatr Dis Treat. 7:151–160.
2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Beecher G, Anderson D and Siddiqi ZA:
Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A
prospective, open-label trial. Neurology. 89:1135–1141.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bourque PR, Pringle CE, Cameron W, Cowan J
and Chardon JW: Subcutaneous immunoglobulin therapy in the chronic
management of myasthenia gravis: A retrospective cohort study. PLoS
One. 11(e0159993)2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dalakas MC: Biologics and other novel
approaches as new therapeutic options in myasthenia gravis: A view
to the future. Ann N Y Acad Sci. 1274:1–8. 2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Steinman L and Zamvil SS: Re-engineering
of pathogenic aquaporin 4-specific antibodies as molecular decoys
to treat neuromyelitis optica. Ann Neurol. 71:287–288.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tandan R, Hehir MK II, Waheed W and Howard
DB: Rituximab treatment of myasthenia gravis: A systematic review.
Muscle Nerve. 56:185–196. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wu X, Tan X, Zhang J and Wang Z, Wu W,
Wang S, Liu Y and Wang Z: The efficacy and safety of Anti-CD20
antibody treatments in relapsing multiple sclerosis: A systematic
review and network meta-analysis. CNS Drugs. 36:1155–1170.
2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Berrih-Aknin S, Ragheb S, Le Panse R and
Lisak RP: Ectopic germinal centers, BAFF and anti-B-cell therapy in
myasthenia gravis. Autoimmun Rev. 12:885–893. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Fleischmann R, Kremer J, Cush J,
Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV,
Zwillich SH and Kanik KS: ORAL Solo Investigators.
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid
arthritis. N Engl J Med. 367:495–507. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sandborn WJ, Ghosh S, Panes J, Vranic I,
Su C, Rousell S and Niezychowski W: Study A3921063 Investigators.
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative
colitis. N Engl J Med. 367:616–624. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wynn D, Kaufman M, Montalban X, Vollmer T,
Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, et al:
Daclizumab in active relapsing multiple sclerosis (CHOICE study): A
phase 2, randomised, double-blind, placebo-controlled, add-on trial
with interferon beta. Lancet Neurol. 9:381–390. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Howard JF Jr, Barohn RJ, Cutter GR,
Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia
ME, Wang JJ, et al: A randomized, double-blind, placebo-controlled
phase II study of eculizumab in patients with refractory
generalized myasthenia gravis. Muscle Nerve. 48:76–84.
2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Howard JF Jr, Utsugisawa K, Benatar M,
Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel
JT, et al: Safety and efficacy of eculizumab in anti-acetylcholine
receptor antibody-positive refractory generalised myasthenia gravis
(REGAIN): A phase 3, randomised, double-blind, placebo-controlled,
multicentre study. Lancet Neurol. 16:976–986. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Vu T, Meisel A, Mantegazza R, Annane D,
Katsuno M, Aguzzi R, Enayetallah A, Beasley KN, Rampal N, James F,
et al: Terminal complement inhibitor ravulizumab in generalized
myasthenia gravis. NEJM Evid 2022. 1.
|
|
28
|
Tsai CY, Wu TH, Yu CL, Lu JY and Tsai YY:
Increased excretions of beta2-microglobulin, IL-6, and IL-8 and
decreased excretion of Tamm-Horsfall glycoprotein in urine of
patients with active lupus nephritis. Nephron. 85:207–214.
2000.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Papp KA, Leonardi C, Menter A, Ortonne JP,
Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH and
Baumgartner S: Brodalumab, an anti-interleukin-17-receptor antibody
for psoriasis. N Engl J Med. 366:1181–1189. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Leonardi C, Matheson R, Zachariae C,
Cameron G, Li L, Edson-Heredia E, Braun D and Banerjee S:
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic
plaque psoriasis. N Engl J Med. 366:1190–1199. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Castro PCS, Magro DO, Nones RB, Furlan TK,
Miranda EF and Kotze PG: Ustekinumab in crohn's disease management:
A Brazilian observational study. Arq Gastroenterol. 59:501–507.
2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gottlieb A, Korman NJ, Gordon KB, Feldman
SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL,
Beutner KR, et al: Guidelines of care for the management of
psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis:
Overview and guidelines of care for treatment with an emphasis on
the biologics. J Am Acad Dermatol. 58:851–864. 2008.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Dhodapkar KM, Banerjee D, Connolly J,
Kukreja A, Matayeva E, Veri MC, Ravetch JV, Steinman RM and
Dhodapkar MV: Selective blockade of the inhibitory Fcgamma receptor
(FcgammaRIIB) in human dendritic cells and monocytes induces a type
I interferon response program. J Exp Med. 204:1359–1369.
2007.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Anthony RM, Nimmerjahn F, Ashline DJ,
Reinhold VN, Paulson JC and Ravetch JV: Recapitulation of IVIG
anti-inflammatory activity with a recombinant IgG Fc. Science.
320:373–376. 2008.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Howard JFJr, Bril V, Vu T, Karam C, Peric
S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M,
et al: Safety, efficacy, and tolerability of efgartigimod in
patients with generalised myasthenia gravis (ADAPT): A multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet Neurol.
20:526–536. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Seldin MF, Alkhairy OK, Lee AT, Lamb JA,
Sussman J, Pirskanen-Matell R, Piehl F, Verschuuren JJGM,
Kostera-Pruszczyk A, Szczudlik P, et al: Genome-Wide association
study of late-onset myasthenia gravis: Confirmation of TNFRSF11A
and Identification of ZBTB10 and Three Distinct HLA Associations.
Mol Med. 21:769–781. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Giraud M, Vandiedonck C and Garchon HJ:
Genetic factors in autoimmune myasthenia gravis. Ann N Y Acad Sci.
1132:180–192. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li HF, Hong Y, Zhang X, Xie Y, Skeie GO,
Hao HJ, Gilhus NE, Liang B, Yue YX, Zhang XJ, et al: Gene
polymorphisms for both auto-antigen and immune-modulating proteins
are associated with the susceptibility of autoimmune myasthenia
gravis. Mol Neurobiol. 54:4771–4780. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Yue YX, Hong Y, Xie Y, Hao HJ, Sui Y, Gu
CK, Zhang X, Gao X, Tang TP, Zhang XJ, et al: Association study
between IL-17A and IL-17F gene polymorphism and myasthenia gravis
in Chinese patients. Neurol Sci. 37:123–130. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Agonia I, Couras J, Cunha A, Andrade AJ,
Macedo J and Sousa-Pinto B: IL-17, IL-21 and IL-22 polymorphisms in
rheumatoid arthritis: A systematic review and meta-analysis.
Cytokine. 125(154813)2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Yu B, Guan M, Peng Y, Shao Y, Zhang C, Yue
X, Zhang J, Yang H, Zou H, Ye W, et al: Copy number variations of
interleukin-17F, interleukin-21, and interleukin-22 are associated
with systemic lupus erythematosus. Arthritis Rheum. 63:3487–3492.
2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ueda H, Howson JM, Esposito L, Heward J,
Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova
G, et al: Association of the T-cell regulatory gene CTLA4 with
susceptibility to autoimmune disease. Nature. 423:506–511.
2003.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Liu FC, Kuo CF, See LC, Tsai HI and Yu HP:
Familial aggregation of myasthenia gravis in affected families: A
population-based study. Clin Epidemiol. 9:527–535. 2017.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Ceribelli A and Selmi C: Epigenetic
methods and twin studies. Adv Exp Med Biol. 1253:95–104.
2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Selmi C, Lu Q and Humble MC: Heritability
versus the role of the environment in autoimmunity. J Autoimmun.
39:249–252. 2012.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Mamrut S, Avidan N, Truffault F, Staun-Ram
E, Sharshar T, Eymard B, Frenkian M, Pitha J, de Baets M, Servais
L, et al: Methylome and transcriptome profiling in Myasthenia
Gravis monozygotic twins. J Autoimmun. 82:62–73. 2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
De Santis M and Selmi C: The therapeutic
potential of epigenetics in autoimmune diseases. Clin Rev Allergy
Immunol. 42:92–101. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Nicoli V and Coppede F: Epigenetics of
thymic epithelial tumors. Cancers (Basel). 15(360)2023.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Bryant A, Atkins H, Pringle CE, Allan D,
Anstee G, Bence-Bruckler I, Hamelin L, Hodgins M, Hopkins H,
Huebsch L, et al: Myasthenia gravis treated with autologous
hematopoietic stem cell transplantation. JAMA Neurol. 73:652–658.
2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Sabre L, Punga T and Punga AR: Circulating
miRNAs as potential biomarkers in myasthenia gravis: Tools for
personalized medicine. Front Immunol. 11(213)2020.PubMed/NCBI View Article : Google Scholar
|
